OSI Systems, Inc. research snapshot
OSIS AI stock analysis currently reads OSI Systems, Inc. as a mid-cap specialized electronics company with three operating segments: Security (Rapiscan screening systems), Healthcare (Spacelabs patient monitoring), and Optoelectronics and Manufacturing. Q3 FY2026 revenue reached a record $453.25 million, up 11% year over year, with EPS of $2.60 beating the $2.54 estimate. The company reported FY2026 nine-month revenue of $1.30 billion and TTM revenue near $1.81 billion, with net income of $152.22 million TTM. At the July 12, 2026 reference price of $216.51 and a verified market capitalization of about $3.57 billion, OSIS trades at 24.77x trailing EPS. The stock is down about 30% from its April 2026 all-time high of $311.72, reflecting margin pressure, project timing, and defense budget uncertainty. This OSIS AI stock forecast is scenario-based, not a precise price prediction, and should be used as an informational research tool, not investment advice.
Current price
$216.51 close reference on July 12, 2026
Market cap
$3.57 billion equity value
AI score
61 / 100
Rating
Mid-cap specialized electronics manufacturer with a diversified security, healthcare, and optoelectronics portfolio and a government contract sales model
Trend status
Down from the April 2026 all-time high of $311.72, trading near the lower end of the 52-week range after a sustained pullback
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | OSI monetizes specialized electronics manufacturing and system integration for security, healthcare, and defense customers through the Rapiscan, Spacelabs, and OSI Optoelectronics brands. Revenue is diversified across three segments, but government contract concentration in Security adds lumpiness. | Medium |
| Moat | The moat comes from FDA and regulatory clearances, long-term government contracts, installed base in airport and border security, and specialized optoelectronics and flex circuit manufacturing. Switching costs are moderate for government customers, lower for commercial OEMs. | Medium |
| Management | CEO Ajay Mehra has led OSI since 2020 after founder Deepak Chopra stepped down. The management team has delivered consistent revenue growth but faces challenges in margin expansion and debt reduction. Insider ownership and incentives should be monitored. | Medium |
| Financial trend | Q3 FY2026 revenue was a record $453.25 million, up 11%. Nine-month FY2026 revenue reached $1.30 billion. TTM revenue is near $1.81 billion. Net income TTM is $152.22 million. The company holds $345.24 million in cash with $116.87% debt-to-equity. | High |
| Valuation | At $216.51, OSIS screened near 24.77x trailing EPS, 4.16x book value, and 2.17x revenue. Forward P/E of 19.68x is lower, suggesting expected EPS growth. The 1.64 PEG ratio indicates a moderate growth premium. | High |
| Technical trend | The stock is well below its 52-week high of $311.72 and near the lower end of the $197 to $312 range. TradingView technicals show a Sell rating on daily and weekly timeframes with a Neutral 1-month reading. | Medium |
| Risk level | Key risks are government contract timing and concentration, margin compression in optoelectronics and manufacturing, debt leverage, healthcare capital equipment cycles, and defense budget uncertainty. | Medium-high |
| AI confidence | Descriptive data confidence is medium-high because SEC filings and quarterly earnings data are available, but some forward-looking estimates and competitive analysis depend on inference. | Medium-high data confidence |
| Investment certainty | OSIS is a well-run electronics company with attractive end markets, but the current price still depends on margin recovery, consistent order flow, and debt reduction. The 30% drop from the April high may create an entry point for patient investors, but near-term catalysts are unclear. | Medium-low |
OSIS AI stock forecast
The OSIS AI stock forecast uses the July 12, 2026 reference price of $216.51, TTM EPS of $9.11, and a three-year earnings multiple framework. The financial_rigor.py model produced a bearish area near $193, a base area near $303, and a bullish area near $416 before dividends, future repurchases, acquisition effects, or multiple changes. These are scenario ranges, not promises.
$400 to $430
More likely if security and healthcare demand accelerates, the optoelectronics segment returns to higher margins, government contract awards increase, the company reduces debt leverage, and the market rewards OSIS with a 30x multiple on higher EPS.
$290 to $315
More likely if revenue grows around 10% annually on steady security spending and healthcare equipment demand, margins stabilize, EPS reaches $12-13 by FY2029, and OSIS trades near 25x forward earnings.
$185 to $200
More likely if government contracts slow, healthcare capital spending weakens, margin pressure in optoelectronics persists, debt costs rise, or the market compresses OSIS toward 20x earnings on lower growth expectations.
OSIS AI technical analysis
OSIS AI technical analysis is bearish to neutral as of the July 12, 2026 data cutoff. TradingView listed the latest close at $216.51, with daily technical indicators in a Sell position, weekly Sell, and monthly Neutral. The stock has corrected approximately 30% from its April 21, 2026 all-time high of $311.72. The beta of 1.34 indicates above-market volatility.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $216.51 | July 12, 2026 close reference used for market cap and valuation math. |
| Immediate support | $197 to $200 | The 52-week low near $197.27 is the closest downside reference level from Yahoo Finance. |
| Secondary support | $180 to $190 | The bearish scenario price area and a potential fill zone if the stock breaks below $197. |
| Deep support | $150 to $160 | The pre-2025 rally base area. A break below $197 would open this zone. |
| Near resistance | $225 to $235 | The June 2026 close near $225 and the nearby moving averages form the first upside test. |
| Upper resistance | $280 to $300 | The analyst target range ($279 to $300) from Citigroup and Argus ratings is a visible upside reference. |
| Moving averages | 50-day and 200-day MAs near $240 to $260 | Price below key MAs confirms the bearish technical setup. Regaining them would signal a trend change. |
| Momentum | RSI likely below 40, MACD bearish | The sustained selloff from the April high has pushed momentum indicators into oversold or weak territory. |
| Volume | Average volume near 260,000 to 317,000 shares | Below-average volume on the selloff can suggest selling exhaustion, but confirmation needs real demand. |
| Volatility | Beta near 1.34, above-market volatility | TradingView listed beta of 1.34, which is moderate for a small-cap industrial name. |
| Invalidation | Close above $260, then above $280 | Regaining the 50-day and 200-day MAs around $240-260 would begin to repair the technical picture. |
OSIS AI trading strategy
The OSIS AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with security and healthcare contract flow, segment margin trends, debt reduction progress, and government budget cycles.
Watch for OSIS to establish a base above $197 support and reclaim the $225 to $235 zone on above-average volume while company updates confirm steady order flow, stable margins, and no deterioration in the security or healthcare pipeline.
A break below $197 support with increasing volume should reduce setup confidence, especially if accompanied by government contract delays, margin warnings, or debt covenant concerns.
If OSIS approaches the $197 to $200 zone without a fundamental deterioration, compare the new price with the verified 24.77x trailing EPS, 19.68x forward P/E, and 2.17x sales to assess whether the selloff has overshot fair value.
Do not treat a lower price as enough if government funding delays, defense budget cuts, or healthcare capex weakness changes the underlying earnings outlook.
Track total revenue by segment (Security, Healthcare, Optoelectronics and Manufacturing), backlog and order awards, segment gross margins, operating cash flow, net debt, share repurchases, and next earnings on or around August 20, 2026.
Position sizing should reflect that OSIS is a small-cap name with moderate liquidity, lumpy government revenue, above-market beta, and significant debt leverage that can amplify downside during sector downturns.
Investment research summary
Customers pay OSI Systems for mission-critical electronic systems and components. Governments and airports pay for Rapiscan security screening to meet regulatory mandates. Hospitals pay for Spacelabs patient monitoring for clinical workflows. OEMs pay for optoelectronics and flex circuits for specialized device manufacturing.
The moat is strongest in security screening where installed base, regulatory certifications, and long-term service contracts create recurring government revenue. It is moderate in healthcare where contract terms and clinical relationships matter. It is thinnest in optoelectronics and manufacturing where OEM customers can switch suppliers.
The thesis fails if government contract awards slow, healthcare capital equipment demand weakens, the optoelectronics segment compresses margins, debt leverage becomes problematic in a rising rate environment, or the stock was overpriced at $311 and is now simply repricing to fair value.
CEO Ajay Mehra has continued the growth trajectory set by founder Deepak Chopra, delivering record quarterly revenue in Q3 FY2026. The next test is whether the company can expand margins, reduce debt leverage, and maintain the security pipeline as defense budgets face political uncertainty.
Security screening demand benefits from global airport expansion, cargo inspection mandates, and homeland security spending. Healthcare patient monitoring grows with aging populations, hospital IT integration, and remote care. Optoelectronics demand follows industrial, aerospace, and medical device OEM cycles.
OSIS is valued as a moderate-growth industrial electronics company at 24.77x trailing EPS. The margin of safety is limited because the stock already priced in growth at higher levels ($311), and the current discount reflects real margin and contract timing concerns that need fundamental confirmation.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $216.51 close on July 12, 2026 | TradingView OSIS overview | July 12, 2026 |
| Market capitalization | $3.57B, verified as $216.51 x 16.49M shares | financial_rigor.py market cap verification | July 12, 2026 |
| Q3 FY2026 revenue | $453.25M, up 11% year over year, record quarterly revenue | TradingView OSIS fundamentals | July 12, 2026 |
| TTM revenue | About $1.81B TTM revenue | Yahoo Finance OSIS key statistics | July 12, 2026 |
| TTM net income | $152.22M TTM net income | Yahoo Finance OSIS key statistics | July 12, 2026 |
| Q3 FY2026 EPS | $2.60 vs $2.54 estimate, 2.29% beat | TradingView OSIS earnings | July 12, 2026 |
| TTM EPS | $9.11 diluted EPS | TradingView OSIS fundamentals | July 12, 2026 |
| Cash and equivalents | $345.24M at most recent quarter | Yahoo Finance OSIS balance sheet | July 12, 2026 |
| Debt-to-equity | 116.87% debt-to-equity | Yahoo Finance OSIS key statistics | July 12, 2026 |
| Enterprise value | $4.37B enterprise value | Yahoo Finance OSIS key statistics | July 12, 2026 |
| Free cash flow | $36.98M levered FCF TTM | Yahoo Finance OSIS key statistics | July 12, 2026 |
| 52-week range | $197.27 to $311.72 | Yahoo Finance OSIS statistics | July 12, 2026 |
| Analyst target | Average $300.29, range $270 to $320 | Yahoo Finance OSIS analysis | July 12, 2026 |
| Valuation math | 24.77x PE, 4.16x PB, 2.17x PS, 19.68x forward P/E | financial_rigor.py valuation verification | July 12, 2026 |
This OSIS AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 12, 2026 and may be wrong if revenue, margins, government contract awards, healthcare capital spending, defense budgets, or market valuation changes.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
